NCT04873180

Brief Summary

detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2020

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 30, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 5, 2021

Completed
Last Updated

May 7, 2021

Status Verified

May 1, 2021

Enrollment Period

6 months

First QC Date

April 30, 2021

Last Update Submit

May 5, 2021

Conditions

Renal Cell Carcinoma

Keywords

Renal Cell CarcinomaSurvivinImmnuohistochemistry

Outcome Measures

Primary Outcomes (1)

  • expression of survivin in neoplastic and adjacent normal renal tissues

    Survivin is highly expressed in neoplastic renal tissues compared to normal ones by immunohistochemical measures..

    april, 2021

Interventions

sectioning and staining of renal neoplasms after nephrectomy operationDIAGNOSTIC_TEST

nephrectomy operations will be done to patients diagnosed as having renel tumors

Eligibility Criteria

Age30 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with symptoms and signs of renal neoplasms admitted to Sohag University hospital and underwent nephrectomy operations. excisional specimens sent to pathology Lab will be sectioned and stained by H\&E. only cases of renal cell carcinoma will be included in the study.

You may qualify if:

  • patients suffer from renal cell carcinomas

You may not qualify if:

  • patients received pre-operative chemotherapy or radiotherapy. patients with insufficient clinical data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maisa Hashem Mohammed

Sohag, 82524, Egypt

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

tissue sections from cases of renal tumors will be preserved in formalin fixed, parraffin embedded blocks.

MeSH Terms

Conditions

Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Maisa H Mohammed, MD

    a lecturer of pathology, Sohag faculty of medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of pathology

Study Record Dates

First Submitted

April 30, 2021

First Posted

May 5, 2021

Study Start

January 1, 2020

Primary Completion

June 30, 2020

Study Completion

December 30, 2020

Last Updated

May 7, 2021

Record last verified: 2021-05

Locations

EG(1)